1.   Introduction

1.1       The Insight Partners Research Report Guidance

1.2       Market Segmentation

2.   Executive Summary

2.1       Key Insights

3.   Research Methodology

3.1       Secondary Research

3.2       Primary Research

3.3       Hypothesis formulation

3.3.1      Macro-economic factor analysis:

3.3.2      Developing base number:

3.3.3      Data Triangulation:

3.3.4      Country level data:

4.   North America Point-of-Care Molecular Testing for Infectious Diseases Market Landscape

4.1       Overview

4.2       PEST Analysis

5.   North America Point-of-Care Molecular Testing for Infectious Diseases Market – Key Market Dynamics

5.1       North America Point-of-Care Molecular Testing for Infectious Diseases Market – Key Market Dynamics

5.2       Market Drivers

5.2.1      Surging Prevalence of Infectious Diseases

5.2.2      Preference for Rapid Diagnostic Solutions

5.3       Market Restraints

5.3.1      Inadequate Reimbursement Scenario

5.4       Market Opportunities

5.4.1      Increasing Focus on R&D and Funding in Infectious Disease Diagnostics

5.5       Future Trends

5.5.1      Rising Number of Product Approvals and Launches

5.6       Impact of Drivers and Restraints:

6.   North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis

6.1       North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue (US$ Million), 2021–2031

6.2       North America Point-of-Care Molecular Testing for Infectious Diseases Market Forecast and Analysis

6.3       Market Share Analysis, By Companies (2023)

6.4       Pricing Analysis

6.5       Pre and Post COVID-19 Impact

6.6       Intellectual Property Rights of Products/Companies

6.6.1      POC Patent Filing

6.7       Novel Companies Entering the Point of Care Testing Market For Infectious Diseases Application

7.   North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Diseases

7.1       HIV Testing

7.1.1      Overview

7.1.2      HIV Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

7.2       Influenza Testing

7.2.1      Overview

7.2.2      Influenza Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

7.3       Sexually Transmitted Diseases Testing

7.3.1      Overview

7.3.2      Sexually Transmitted Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

7.3.2.1  North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sexually Transmitted Diseases Testing

7.4       Hepatitis C Virus Testing

7.4.1      Overview

7.4.2      Hepatitis C Virus Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

7.5       Tropical Diseases Testing

7.5.1      Overview

7.5.2      Tropical Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

7.5.2.1  North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Tropical Diseases Testing

7.6       Respiratory Infection Testing

7.6.1      Overview

7.6.2      Respiratory Infection Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

7.7       Hospital Acquired Infections

7.7.1      Overview

7.7.2      Hospital Acquired Infections: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

7.8       Strep

7.8.1      Overview

7.8.2      Strep: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

7.9       Others

7.9.1      Overview

7.9.2      Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

8.   North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Technology

8.1       Lateral Flow Assay

8.1.1      Overview

8.1.2      Lateral Flow Assay: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

8.2       Dipsticks

8.2.1      Overview

8.2.2      Dipsticks: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

8.3       Microfluidics

8.3.1      Overview

8.3.2      Microfluidics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

8.4       Molecular Diagnostics

8.4.1      Overview

8.4.2      Molecular Diagnostics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

8.4.2.1  North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Molecular Diagnostics

8.4.2.1.1   North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Polymerase Chain Reactions (PCR)

8.5       Immunoassays

8.5.1      Overview

8.5.2      Immunoassays: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

8.6       Solid Phase

8.6.1      Overview

8.6.2      Solid Phase: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

8.7       Others

8.7.1      Overview

8.7.2      Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

9.   North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Prescription Testing

9.1       Prescription Based Testing

9.1.1      Overview

9.1.2      Prescription Based Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

9.2       OTC Testing

9.2.1      Overview

9.2.2      OTC Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

10. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Sample

10.1     Blood Sample

10.1.1    Overview

10.1.2    Blood Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

10.2     Urine Sample

10.2.1    Overview

10.2.2    Urine Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

10.3     Nasal and Oropharyngeal Swabs Sample

10.3.1    Overview

10.3.2    Nasal and Oropharyngeal Swabs Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

10.4     Others

10.4.1    Overview

10.4.2    Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

11. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by End User

11.1     Hospitals and Clinics

11.1.1    Overview

11.1.2    Hospitals and Clinics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

11.1.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Hospitals and Clinics

11.2     Home Care Settings

11.2.1    Overview

11.2.2    Home Care Settings: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

11.3     Ambulatory and Urgent Care Facilities

11.3.1    Overview

11.3.2    Ambulatory and Urgent Care Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

11.4     Nursing Home and Assisted Living Facilities

11.4.1    Overview

11.4.2    Nursing Home and Assisted Living Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

11.5     Research Laboratories

11.5.1    Overview

11.5.2    Research Laboratories: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

11.6     Diagnostics Centers

11.6.1    Overview

11.6.2    Diagnostics Centers: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

12. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Distribution Channel

12.1     E-Com Platforms

12.1.1    Overview

12.1.2    E-Com Platforms: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

12.2     Retail Channel and Pharmacies

12.2.1    Overview

12.2.2    Retail Channel and Pharmacies: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

12.3     Others

12.3.1    Overview

12.3.2    Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

13. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Country Analysis

13.1     North America

13.1.1    North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Countries

13.1.2    North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue and Forecast and Analysis – by Country

13.1.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue and Forecast and Analysis – by Country

13.1.2.2 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

13.1.2.2.1 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Diseases

13.1.2.2.2 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sexually Transmitted Diseases Testing

13.1.2.2.3 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Tropical Diseases Testing

13.1.2.2.4 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Technology

13.1.2.2.5 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Molecular Diagnostics

13.1.2.2.6 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Polymerase Chain Reactions (PCR)

13.1.2.2.7 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Prescription Testing

13.1.2.2.8 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sample

13.1.2.2.9 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by End User

13.1.2.2.10              United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Hospitals And Clinics

13.1.2.2.11              United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Distribution Channel

13.1.2.3 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

13.1.2.3.1 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Diseases

13.1.2.3.2 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sexually Transmitted Diseases Testing

13.1.2.3.3 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Tropical Diseases Testing

13.1.2.3.4 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Technology

13.1.2.3.5 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Molecular Diagnostics

13.1.2.3.6 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Polymerase Chain Reactions (PCR)

13.1.2.3.7 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Prescription Testing

13.1.2.3.8 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sample

13.1.2.3.9 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by End User

13.1.2.3.10              Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Hospitals And Clinics

13.1.2.3.11              Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Distribution Channel

13.1.2.4 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

13.1.2.4.1 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Diseases

13.1.2.4.2 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sexually Transmitted Diseases Testing

13.1.2.4.3 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Tropical Diseases Testing

13.1.2.4.4 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Technology

13.1.2.4.5 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Molecular Diagnostics

13.1.2.4.6 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Polymerase Chain Reactions (PCR)

13.1.2.4.7 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Prescription Testing

13.1.2.4.8 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sample

13.1.2.4.9 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by End User

13.1.2.4.10              Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Hospitals And Clinics

13.1.2.4.11              Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Distribution Channel

14. North America Point-Of-Care Molecular Testing for Infectious Diseases Market – Industry Landscape

14.1     Overview

14.2     Growth Strategies in North America Point-Of-Care Molecular Testing for Infectious Diseases Market

14.3     Organic Growth Strategies

14.3.1    Overview

14.4     Inorganic Growth Strategies

14.4.1    Overview

15. Company Profiles

15.1     Abbott Laboratories

15.1.1    Key Facts

15.1.2    Business Description

15.1.3    Products and Services

15.1.4    Financial Overview

15.1.5    SWOT Analysis

15.1.6    Key Developments

15.2     Agilent Technologies Inc

15.2.1    Key Facts

15.2.2    Business Description

15.2.3    Products and Services

15.2.4    Financial Overview

15.2.5    SWOT Analysis

15.2.6    Key Developments

15.3     Becton Dickinson and Co

15.3.1    Key Facts

15.3.2    Business Description

15.3.3    Products and Services

15.3.4    Financial Overview

15.3.5    SWOT Analysis

15.3.6    Key Developments

15.4     Bio-Rad Laboratories Inc

15.4.1    Key Facts

15.4.2    Business Description

15.4.3    Products and Services

15.4.4    Financial Overview

15.4.5    SWOT Analysis

15.4.6    Key Developments

15.5     Cardinal Health Inc

15.5.1    Key Facts

15.5.2    Business Description

15.5.3    Products and Services

15.5.4    Financial Overview

15.5.5    SWOT Analysis

15.5.6    Key Developments

15.6     Danaher Corp

15.6.1    Key Facts

15.6.2    Business Description

15.6.3    Products and Services

15.6.4    Financial Overview

15.6.5    SWOT Analysis

15.6.6    Key Developments

15.7     Cue Health Inc

15.7.1    Key Facts

15.7.2    Business Description

15.7.3    Products and Services

15.7.4    Financial Overview

15.7.5    SWOT Analysis

15.7.6    Key Developments

15.8     QuidelOrtho Corp

15.8.1    Key Facts

15.8.2    Business Description

15.8.3    Products and Services

15.8.4    Financial Overview

15.8.5    SWOT Analysis

15.8.6    Key Developments

15.9     Thermo Fisher Scientific Inc

15.9.1    Key Facts

15.9.2    Business Description

15.9.3    Products and Services

15.9.4    Financial Overview

15.9.5    SWOT Analysis

15.9.6    Key Developments

15.10  F. Hoffmann-La Roche Ltd

15.10.1  Key Facts

15.10.2  Business Description

15.10.3  Products and Services

15.10.4  Financial Overview

15.10.5  SWOT Analysis

15.10.6  Key Developments

16. Appendix

16.1     About The Insight Partners

16.2     Glossary of Terms

1.1.2      List of Tables

Table 1.   North America Point-of-Care Molecular Testing for Infectious Diseases Market Segmentation

Table 2.   Infectious Diseases and Fundings

Table 3.   North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Table 4.   Market Share Analysis, By Companies (2023)

Table 5.   Pricing Analysis

Table 6.   List of Patent filed by Companies

Table 7.   North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Diseases

Table 8.   North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sexually Transmitted Diseases Testing

Table 9.   North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Tropical Diseases Testing

Table 10. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Technology

Table 11. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Molecular Diagnostics

Table 12. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Polymerase Chain Reactions (PCR)

Table 13. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Prescription Testing

Table 14. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sample

Table 15. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by End User

Table 16. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Hospitals and Clinics

Table 17. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel

Table 18. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Country

Table 19. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Diseases

Table 20. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sexually Transmitted Diseases Testing

Table 21. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Tropical Diseases Testing

Table 22. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Technology

Table 23. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Molecular Diagnostics

Table 24. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Polymerase Chain Reactions (PCR)

Table 25. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Prescription Testing

Table 26. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sample

Table 27. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by End User

Table 28. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Hospitals And Clinics

Table 29. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel

Table 30. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Diseases

Table 31. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sexually Transmitted Diseases Testing

Table 32. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Tropical Diseases Testing

Table 33. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Technology

Table 34. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Molecular Diagnostics

Table 35. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Polymerase Chain Reactions (PCR)

Table 36. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Prescription Testing

Table 37. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sample

Table 38. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by End User

Table 39. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Hospitals And Clinics

Table 40. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel

Table 41. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Diseases

Table 42. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sexually Transmitted Diseases Testing

Table 43. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Tropical Diseases Testing

Table 44. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Technology

Table 45. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Molecular Diagnostics

Table 46. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Polymerase Chain Reactions (PCR)

Table 47. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Prescription Testing

Table 48. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sample

Table 49. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by End User

Table 50. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Hospitals And Clinics

Table 51. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel

Table 52. Recent Organic Growth Strategies in North America Point-Of-Care Molecular Testing for Infectious Diseases Market

Table 53. Recent Inorganic Growth Strategies in the North America Point-Of-Care Molecular Testing For Infectious Diseases Market

Table 54. Glossary of Terms, Infectious Disease Diagnostics Market

1.1.3      List of Figures

Figure 1. North America Point-of-Care Molecular Testing for Infectious Diseases Market Segmentation, by Country

Figure 2. PEST Analysis

Figure 3. Impact Analysis of Drivers and Restraints

Figure 4. North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue (US$ Million),  2021–2031

Figure 5. Pre and Post COVID-19 Impact

Figure 6. Patents filed by Top Companies for POC

Figure 7. Number of Patent Families for POC

Figure 8. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) – by Diseases, 2023 and 2031

Figure 9. HIV Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 10.           Influenza Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 11.           Sexually Transmitted Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 12.           Hepatitis C Virus Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 13.           Tropical Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 14.           Respiratory Infection Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 15.           Hospital Acquired Infections: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 16.           Strep: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 17.           Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 18.           North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) – by Technology, 2023 and 2031

Figure 19.           Lateral Flow Assay: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 20.           Dipsticks: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 21.           Microfluidics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 22.           Molecular Diagnostics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 23.           Immunoassays: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 24.           Solid Phase: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 25.           Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 26.           North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) – by Prescription Testing, 2023 and 2031

Figure 27.           Prescription Based Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 28.           OTC Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 29.           North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) – by Sample, 2023 and 2031

Figure 30.           Blood Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 31.           Urine Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 32.           Nasal and Oropharyngeal Swabs Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 33.           Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 34.           North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) – by End User, 2023 and 2031

Figure 35.           Hospitals and Clinics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 36.           Home Care Settings: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 37.           Ambulatory and Urgent Care Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 38.           Nursing Home and Assisted Living Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 39.           Research Laboratories: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 40.           Diagnostics Centers: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 41.           North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) – by Distribution Channel, 2023 and 2031

Figure 42.           E-Com Platforms: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 43.           Retail Channel and Pharmacies: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 44.           Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 45.           North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Key Countries, 2023 and 2031 (%)

Figure 46.           United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 47.           Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 48.           Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)

Figure 49.           Growth Strategies in North America Point-Of-Care Molecular Testing for Infectious Diseases Market